Michael Brunsteiner
About Michael Brunsteiner
Michael Brunsteiner is a Principal Scientist at Celeris Therapeutics in Graz, Austria, where he has worked since 2022. He has extensive experience in biopharmaceuticals, molecular dynamics simulations, and computational chemistry, with a career spanning over two decades in various research roles.
Work at Celeris Therapeutics
Michael Brunsteiner has been serving as Principal Scientist at Celeris Therapeutics since 2022. His role focuses on advancing research in the field of biopharmaceuticals. Based in Graz, Styria, Austria, he contributes to the company's mission of developing innovative therapeutic solutions. His expertise in the aggregation and stability of bio-pharmaceuticals supports the formulation of poorly soluble drugs, which is critical for enhancing drug delivery and efficacy.
Education and Expertise
Michael Brunsteiner holds a Master of Science in Biotechnology from the University for Natural Resources and Life Sciences, Vienna, which he completed from 1994 to 1999. He furthered his education at University College London (UCL), where he earned a PhD in computational chemistry from 2000 to 2003. His academic background provides a strong foundation for his expertise in predicting crystal structures, polymorphs, and solid-state properties of pharmaceuticals.
Background in Research and Development
Before joining Celeris Therapeutics, Michael Brunsteiner accumulated extensive experience in the pharmaceutical research sector. He worked as a Principal Scientist at Research Center Pharmaceutical Engineering GmbH from 2010 to 2022, where he focused on the design and evaluation of protein degraders (PROTACs). His previous roles include positions at Vernalis and the University of Illinois at Chicago, where he contributed to various research projects related to bio-pharmaceuticals.
Achievements in Molecular Simulation and Pharmacokinetics
Michael Brunsteiner specializes in molecular dynamics simulations, including force field development and estimation of free energies such as solvation and binding. He has developed skills in physiologically based pharmacokinetic modeling and crystallization of bio-pharmaceuticals using PBE models. His work has implications for improving the stability and delivery of pharmaceutical compounds, particularly in the context of poorly soluble drugs.